Nxera Pharma has received $10 million from pharmaceutical company AbbVie under the terms of the multi-target discovery collaboration on neurological diseases, Nxera has announced. Nxera and AbbVie entered the multi-target collaboration in 2022, leveraging Nxera’s NxWave platform to discover novel medicines targeting G protein-coupled receptors (GPCRs) associated with neurological disease. This current milestone relates to […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!